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ABSTRAK 
 
PENGHASILAN DAN PENGESAHAN SOAL SELIDIK KEPATUHAN 
INSULIN (IAQDM) DAN PENGENALPASTIAN FAKTOR-FAKTOR 
BERKAITAN DENGAN KETIDAKPATUHAN DALAM KALANGAN 
PESAKIT KENCING MANIS JENIS 2 
 
Pengenalan:  
Prevalen penyakit kencing manis jenis 2 (T2DM) sedang meningkat di seluruh dunia 
dan di dalam negara. Walaupun pelbagai rawatan telah diberi untuk mengawal tahap 
glukos dalam darah, sasaran glisemik yang ditetapkan masih tidak tercapai. Buat 
masa sekarang, terapi insulin menjadi terapi utama kerana keberkesanannya dalam 
mengawal tahap glukos dalam darah. Walau bagaimanpun, rawatan insulin secara 
suntikan sangat komplek dan boleh menyumbang kepada masalah ketidakpatuhan 
terhadap rawatan insulin dalam kalangan pesakit diabetes. 
 
Objektif: Untuk menghasil dan mengesahkan satu soal selidik baru untuk mengukur 
kepatuhan terhadap terapi insulin dalam kalangan pesakit kencing manis jenis 2. 
Kajian ini juga bertujuan untuk menentukan kadar ketidakpatuhan, kawalan glisemik, 
dan faktor-faktor yang berkaitan dengan terapi insulin.  
 
Metodologi: Kajian ini menggunakan kaedah secara kualitatif di awal kajian untuk 
memilih tema yang sesuai bagi menghasilkan IAQDM dan kajian selainnya 
menggunakan kaedah kuantitatif. Temubual telah dijalankan kepada 30 orang pesakit 
 
 
xx 
kencing manis jenis 2 yang menerima terapi insulin menggunakan panduan soal 
selidik semi-struktur untuk temuduga. Item untuk IAQDM baru telah dipilih dari 
temuduga pesakit, kajian literatur, dan konsultasi dengan pakar. 
 
Soal Selidik IAQDM telah diukur kesahihannya terhadap 156 orang pesakit kencing 
manis jenis 2 yang menerima rawatan insulin di Pusat Diabetes, Hospital Universiti 
Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. Tahap ketidakpatuhan terhadap 
terapi insulin, kawalan glisemik dan faktor-faktor berkaitan dengan ketidakpatuhan 
terapi insulin telah diukur dalam kalangan 355 orang pesakit kencing manis jenis 2. 
Transkrip dari awal kajian telah dianalisa untuk tema yang berkaitan menggunakan 
perisian NVivo versi 10.0. Data untuk sosiodemografi, kadar ketidakpatuhan insulin, 
kawalan glisemik, dan faktor-faktor yang berkaitan dengan terapi insulin telah 
dianalisa secara kuantitatif menggunakan “Statistical Package of Social Science” 
(SPSS) versi 22. 
 
Keputusan: IAQDM mengandungi 35 item yang terdiri dari empat domain: domain 
1 (halangan terhadap suntikan insulin), domain 2 (pemantauan kendiri insulin dan 
glukos dalam darah), domain 3 (kepatuhan terhadap suntikan insulin) dan domain 4 
(pelarasan pemakanan dalam terapi insulin). Nilai keseluruhan Cronbach’s alpha 
bagi 35 soalan IAQDM ialah 0.82. Cronbach’s alpha untuk keempat-empat domain 
masing-masing adalah 0.82, 0.88, 0.85 dan 0.82. Kadar ketidakkepatuhan terhadap 
terapi insulin dalam kalangan pesakit kencing manis jenis 2 adalah 81%. Majoriti 
(98%) pesakit diabetes jenis 2 yang menerima rawatan insulin tidak mencapai 
sasaran tahap HbA1c < 6.5%. Jangka masa penggunaan insulin, kekerapan suntikan 
 
 
xxi 
insulin dan tahap gula semasa berpuasa telah dikenalpasti sebagai faktor yang bebas 
dan ketara yang mempengaruhi ketidakpatuhan terhadap terapi insulin. 
 
Kesimpulan: Satu Soal Selidik baru IAQDM dengan ciri-ciri psikometrik yang 
sangat baik untuk mengukur kepatuhan terhadap terapi insulin telah berjaya 
dihasilkan. Kepatuhan terhadap terapi insulin dalam kalangan pesakit kencing manis 
jenis 2 sangat rendah.  Pengenalpastian faktor-faktor yang mempengaruhi 
ketidakpatuhan insulin boleh memberi panduan yang amat berguna untuk 
penyaringan, pengurusan, pemantauan, dan penambahbaikan kepatuhan kepada 
terapi insulin. 
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ABSTRACT 
 
DEVELOPMENT AND VALIDATION OF INSULIN ADHERENCE 
QUESTIONNAIRE (IAQDM) AND DETERMINATION OF FACTORS 
ASSOCIATED WITH NON-ADHERENCE AMONG PATIENTS WITH TYPE 
2  DIABETES 
 
Introduction: Prevalence of type 2 diabetes mellitus (T2DM) is increasing 
worldwide and locally. Although various treatments were prescribed to control blood 
glucose level, the glycaemic target is still not achieved. At present, insulin therapy 
becomes the mainstay of treatment because of its effectiveness to control blood 
glucose. However, insulin injection is complex and can contribute to non-adherence 
problem among insulin treated patients with diabetes. 
 
Objective: To develop and validate a new questionnaire to measure adherence with 
insulin therapy in patients with T2DM. This study also aimed to determine rate of 
non-adherence, glycaemic control and factors associated with insulin therapy.  
 
Methodology: This study used qualitative design in the initial part of the study to 
choose appropriate themes for the IAQDM and quantitative design was utilised for 
the rest of the study. Interviews were conducted among 30 patients with T2DM on 
insulin therapy using developed and validated semi-structured interview guide. Items 
for the new IAQDM were selected from patients’ interviews, literature reviews, and 
consultation with the experts. The IAQDM was validated among 156 patients with 
T2DM on insulin therapy at the Diabetic Centre, Hospital Universiti Sains Malaysia, 
 
 
xxiii 
Kubang Kerian, Kelantan, Malaysia. Rate of insulin non-adherence, glycaemic 
control and factors associated with insulin non-adherence were measured in 355 
patients with type 2 diabetes mellitus. Transcript data from the initial interviews were 
analysed for relevant themes using NVivo software version 10.0. Data for 
sociodemography, insulin non-adherence rate, glecemic control and factors 
associated with insulin therapy were analysed quantitatively using Statistical Package 
of Social Science (SPSS) version 22. 
 
Result: The IAQDM consisted of 35 items and four domains: domain 1 (barriers 
with insulin injection), domain 2 (self-monitoring of insulin and blood glucose), 
domain 3 (adherence with insulin injection) and domain 4 (dietary adjustment with 
insulin therapy). Overall Cronbach’s alpha value for all the 35 items in the IAQDM 
was 0.82. Cronbach’s alpha values for each domain are 0.82, 0.88, 0.85 and 0.82 
respectively. Non-adherence rate with insulin therapy among patients with type 2 
diabetes was 81%. Majority (98%) of patients on insulin therapy did not achieve the 
target HbA1c of < 6.5%.  Duration of insulin therapy, frequency of insulin injections 
and fasting plasma glucose were identified as independent and significant factors to 
non-adherence with insulin therapy. 
 
Conclusion: A new IAQDM with very good psychometric properties to measure 
adherence with insulin therapy has been developed. Adherence with insulin therapy 
and glycemic control among patients with T2DM were very poor.  Identification of 
several factors contributed to insulin non-adherence can provide a very useful guide 
for screening, managing, monitoring, and improving adherence with insulin therapy. 
 1 
 
 
CHAPTER 1 
INTRODUCTION 
1.1 Background of the study 
 
Type 2 diabetes mellitus (T2DM) continues to increase worldwide and in 
Malaysia. Globally, in 1995, the number of population in the developing country 
affected by diabetes was estimated to be 135 million in the year 2000 and 
increased to 154 million in the year 2025 (King et al., 1998; Mafauzy, 2006). It 
is the most common disease causing significant mortality and morbidity is in 
nearly all the countries (Vijan et al., 2005; Danaei et al., 2011; Whiting et al., 
2011).  
 
In Malaysia, the First National Health and Morbidity Survey (NHMS) 1986 
reported a prevalence of diabetes mellitus of 6.3% and in the Second NHMS I in 
1996, the prevalence had risen to 8.2% (Mafauzy, 2006). Based on the latest 
results of the NHMS 2011 and projections by the Disease Control Division, 
Ministry of Health (MOH), the prevalence of diabetes among adults in Malaysia 
is projected to rise to 21.6% by the year 2020. 
 
Furthermore, studies in Malaysian had shown that diabetes was most prevalent 
amongst Indians (38%) and Malays (24%) with the current overall prevalent of 
23% compared to the year 2006 with only 12% (Wan Nazaimoon et al., 2013).  
 
 
 
2 
Type 2 diabetes mellitus (T2DM) is a chronic disease and causes many problems 
such as financial, psychosocial and disability to the sufferer, family and 
community (Boyle et al., 2010). Short-term complications of T2DM are 
hypoglycemia and hyperosmolar hyperglycemic nonketotic syndrome, which is 
very high blood glucose. Long term complications of T2DM are macrovascular 
complications (coronary artery disease, peripheral arterial disease, and stroke) 
and microvascular complications (diabetic nephropathy, neuropathy, and 
retinopathy) (Fowler, 2008). Morbidity and mortality substantially increased 
with elevation of blood glucose (Lavernia, 2008). Therefore, proper 
management and treatment are very important aspect in dealing with T2DM 
especially with insulin therapy. 
 
At the beginning of the diagnosis, majority of patients can control their 
glycaemic status with diet, exercise and oral hypoglycaemic agents (OHA). 
However, sooner or later, these T2DM patients will eventually need to take 
insulin, as their ability to produce their own insulin from pancreatic beta-cells 
increasingly declined (Hirsch et al, 2005, Hamaty, 2011). 
 
Most importantly, T2DM is a progressive disease and treatment with oral 
hypoglycaemic agents often lose their effectiveness with increased duration of 
disease. Consequently, there is a need to add insulin therapy to maintain 
glycaemic control. The use of insulin therapy among patients with T2DM has 
continued to increase with the awareness of the need to maintain strict glycaemic 
control and good adherence towards prevention of acute and chronic 
complications of diabetes (Ministry Of Health Malaysia, 2010).  
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Even though the use of insulin has increased, its use is still generally low in 
Malaysia and varies across different states in the country. This happens because 
of low acceptance from health care providers, patients, family members, 
probably due to lack of knowledge, awareness, guidance and support. Therefore, 
diabetes focused health education and counselling will hopefully improve 
awareness, acceptance and adherence to insulin therapy among T2DM patients. 
 
Insulin therapies have now become a common prescription for out-patient 
departments (DeWitt & Dugdale, 2003). Many uncontrolled T2DM patients with 
symptoms, regardless whether haemoglobin A1c (HbA1c) more than 10% or 
fasting blood sugar (FBS) of more than 13 mmol/L, will be started on 
subcutaneous insulin injection (Practical guide to insulin therapy in T2DM, 
2010).  
 
Insulin therapy is very complex if not properly guided. Usually, T2DM will start 
with a single type of insulin therapy such as subcutaneous glargine (Lantus®), 
detemir (Levemir®), or insulatard (NPH®) (DeWitt & Dugdale, 2003, Hamaty, 
2011). These types of insulin must be injected before bedtime. The aim for these 
types of insulin is to reduce fasting blood sugar till near normal, about four to six 
mmol/L (4 – 6 mmol/L) without hypoglycaemic symptoms. Subsequently, if a 
single type of insulin still cannot achieve the near normal target, most T2DM 
patients will need to inject two times, three times, or four times a day. 
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Furthermore, even though the majority of T2DM at Diabetic Centre, Hospital 
Universiti Sains Malaysia were prescribed with more than one injection per day, 
glycaemic status are still unsatisfactory. Three years data from 2012 to 2014 
revealed that majority of patients had Glycosylated Haemoglobin A1c (HbA1c) 
levels of more than 8% (Figure 1.1).  
 
 
Figure 1. 1 HbA1c result from patients with T2DM Attending Diabetic 
Centre, HUSM, Kelantan, Malaysia from 2012 to 2014  
(Data from the Diabetic Centre, HUSM, 2015). 
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1.2 Justification of the study 
 
At the moment, there is no standard tool for measuring adherence among 
patients with T2DM on insulin therapy. Even though numerous studies had been 
conducted in relation with insulin therapy (Bradley et al, 2007, Naegeli & 
Haynes, 2010, Franz M, 2010, Nishigaki et al, 2012), none was focusing 
specifically on measuring insulin adherence. Since adherence is very crucial for 
the success of diabetic therapy (Chisholm-Burns & Spivey, 2012), availability of 
a new tool to measure insulin is certainly justified. Therefore, this study has been 
conducted to develop a new tool to measure adherence among patients with 
T2DM on insulin therapy. 
 
Non-adherence to medication can resulted in failure of patient’s condition to 
improve, worsen or relapse (especially in long term therapy), and this effect has 
negative economic impact on the entire health care system (Chisholm-Burns & 
Spivey, 2012). Obtaining information about the level of non-adherence among 
T2DM with insulin therapy is a first step in formulating intervention program 
among insulin treated diabetes patients. Given this point, vigilant assessment is 
critical in planning for the interventions needed, to improve effectiveness of 
pharmacological care, and to safeguard the sustainability of healthcare systems 
especially in patients with insulin therapy. 
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Ability of health care practitioners such as clinicians, pharmacists, nurses, 
dieticians and others to identify and document insulin non-adherence and its 
associated factors among patients with T2DM is very important for the 
successful outcomes of therapy. These documentations using evidence-based 
approach can provide further understanding on the complex and dynamic 
behaviour of adherence with insulin therapy. Therefore, prevention and 
intervention strategies can be implemented to reduce problems, complications, 
disease progression, cost, morbidity and mortality.  
 
1.3 Rationale of the study 
 
The rationale of conducting this study was to obtain more information regarding 
adherence among patients with T2DM on insulin therapy. Furthermore, since 
there was no specific assessment tool to be used in assessing adherence to insulin 
therapy, especially in the local population, a new tool was developed and 
validated. Although quality of life of patients has been constantly targeted as an 
important matter in the patients’ treatment management (Pera, 2011, Oliva et al., 
2012), understanding regarding basics of insulin therapy is still limited. In 
addition, most of the available information was obtained from different settings 
(Wei, et al., 2002, Farsaei, et al., 2014) which may not be applicable locally.  
Adherence is a dynamic and complex behaviour and may differ with different 
setting and population. Thus, the findings of this study will serve the purpose of 
providing as much information as possible regarding adherence in the local 
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setting to improve the services provided by the health care practitioners among 
patients with type 2 diabetes on insulin therapy. 
 
 
 
1.4 Conceptual framework of the study 
 
The modified Health Belief model (HBM) (Figure 1.2) was used to study 
patients’ responses to symptoms and their behaviour in response to diagnosed 
illness, particularly adherence with medical regimens were mainly used in the 
development of the questionnaire (Janz and Becker, 1984, Carpenter, 2010). The 
HBM is generally effective in identifying factors associated with the adoption of 
preventive action in a variety of different populations. The model also relates 
patient’s susceptibility to illness, severity of consequences, and benefits and 
barriers to adherence with prescribed therapy. 
 
The HBM by Janz and Becker (1984) is a framework for understanding patient 
adherence to health behaviours. The HBM focus on two aspects of a person’s 
conceptualization of health and health behaviour which are threat perception and 
behavioural evaluation. Threat perception is dependent on perceived 
susceptibility to illness and anticipated severity of the consequences.  For the 
behavioural evaluation, it concerns the benefits of a health behaviour and the 
barriers to enacting the behaviour’s (Carpenter, 2010). Therefore, according to 
the HBM, the likelihood of individuals with T2DM adhering to their regimens 
may be determined by five factors. 
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The first factor, which is susceptibility to illness, refers to the perception of 
vulnerability to diabetes and its complications. This includes patients’ perception 
of chance that they may have for developing problems due to diabetes. The 
second factor is severity, which is the perception of diabetes as a serious illness, 
ranging from perceiving few complications to viewing diabetes as a life-
threatening disease. The third factor is benefits of adherent behaviour which 
concerns the perception that the regimen is effective, so that the individual feels 
physically better from taking medications.  
 
The fourth factor is barriers to adherence. This refers to the perceived cost of 
adhering to a regimen and how inconvenient the regimen is perceived to be. 
Lastly, cues to action concerns either external (e.g., time of day, reminders from 
family) or internal (e.g., feeling high and low blood sugars) cues that the 
individual associates with taking action. However, it was noted that the cues to 
action was the most underdeveloped factor and rarely measured in research 
(Carpenter, 2010).    
 
Inconsistent results have been obtained in several studies which investigated risk 
perception and adherence to recommended diabetes management activities in 
adults (Janz & Becker, 1984, Woolridge et al., 1992). These findings highlight 
the importance of modifying and examining individual components of health 
beliefs, rather than directly using the HBM (Carpenter, 2010).    
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Figure 1. 2 Modified conceptual framework of the Health Belief Model on  
                   insulin adherence among patients with T2DM 
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1.5 Research questions 
 
1. Is the newly developed Insulin Adherence Questionnaire valid and reliable? 
2. What is the rate of non-adherence among patients with T2DM on insulin 
therapy? 
3. What is the rate of glycaemic control among patients with T2DM on insulin 
therapy? 
4. What are the factors associated with non-adherence with insulin therapy? 
1.6 Research objectives 
1.6.1 General objectives 
The general objective is to develop and validate a new questionnaire to measure 
adherence with insulin therapy in patients with T2DM at the Diabetic Centre, 
Hospital Universiti Sains Malaysia, Kelantan, Malaysia. 
1.6.2 Specific objectives 
1. To develop and validate a new Insulin Adherence Questionnaire to 
measure adherence with insulin therapy. 
2. To determine rate of non-adherence among T2DM on insulin therapy.   
3. To determine rate glycaemic control among patients with T2DM on 
insulin therapy.  
4. To identify factors associated with non-adherence with insulin therapy. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Definition and causes of T2DM 
 
Type 2 diabetes mellitus is a complex metabolic disorder resulting from relatively 
decreased pancreatic insulin secretion, insulin action or insulin resistance (Inzucchi, 
2002). It has serious complications and reduce life expectancy by 8–10 years (Astrup 
and Finer, 2000). It is the most prevalent form of diabetes (90–95%) and rapidly 
becoming one of the major disease in the world (LaSalle, 2010).  
 
Type 2 diabetes is the condition in which the body does not produce or properly use 
insulin (Simo and Hernández, 2002, Organization, 2006). Insulin is a hormone that is 
required to convert glucose into energy needed for daily life. Insulin insensitivity is 
an early phenomenon partly related with obesity, with gradual decline of pancreatic 
β-cell function over time before the onset of clinical hyperglycaemia (Alberti and 
Zimmet, 1998; Scheen, 2003, Hirsch et al., 2005, Stumvoll et al., 2005, Inzucchi et 
al, 2012).  
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The causes of diabetes stem from both from genetics and environmental factors. 
Obesity and lack of exercise also appear to play important roles (Stern, 1995, Astrup 
and Finer, 2000,  Chen et al., 2012).  
 
 
 
2.2 Pathophysiology of T2DM 
 
Type 2 diabetes mellitus is a heterogeneous syndrome characterized by abnormalities 
in carbohydrate and fat metabolism. It is characterised by high blood glucose in the 
context of insulin resistance and relative insulin deficiency (Meltzer et al., 1998, 
Rodbard et al., 2009). The causes of T2DM are complex and multifactorial and 
include both genetic and environmental elements that affect beta-cell function and 
tissue (muscle, liver, adipose tissue, and pancreas) which in turn affect insulin 
sensitivity. Majority of individuals suffering from T2DM are obese with central 
visceral adiposity. Therefore, adipose tissue plays a crucial role in the pathogenesis 
of T2DM (Scheen, 2003).  
 
Type 2 diabetes mellitus is characterized by a combination of peripheral insulin 
resistance and inadequate insulin secretion by pancreatic beta cells. Insulin 
resistance, which has been attributed to elevated levels of free fatty acids and pro-
inflammatory cytokines in plasma, leads to decreased glucose transport into muscle 
cells, elevated hepatic glucose production, and increased breakdown of fat 
(American Diabetes Association, 2008, American Diabetes Association, 2009, 
American Diabetes Association, 2010). 
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For T2DM to occur (Figure 2.1), both insulin resistance and inadequate insulin 
secretion must exist. For example, all overweight individuals have insulin resistance, 
but diabetes only develops in those who cannot increase insulin secretion sufficiently 
to compensate for their insulin resistance. Their insulin concentrations may be high, 
yet inappropriately low for their level of glycaemia (Rodbard et al., 2009, MOH, 
2016). 
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Figure 2. 1 Pathophysiology of T2DM 
(Adapted from Hope, 2012) 
2.3 Diagnosis of T2DM 
 
Diagnosis of diabetes mellitus can be made through clinical presentation such as 
increased thirst and urine volume, recurrent infections, unexplained weight loss, and 
in severe cases, drowsiness and coma. Furthermore, high levels of glycosuria are 
usually present (Stride et al., 2005, Clinical practice guidelines, 2016).  
 
According to The Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus (Alberti and Zimmet, 1998, The International Expert Committee, 2009), 
diabetes may be diagnosed in three ways: symptoms of diabetes plus casual plasma 
glucose concentrations ≥ 11.1 mmol/L, fasting plasma glucose (FPG) ≥ 7.0 mmol/L, 
or two hours plasma glucose (2 - hPG) ≥ 11.1 mmol/L during an oral glucose 
tolerance test (OGTT). 
 
In addition, the diagnosis of diabetes in an asymptomatic subject should never be 
made on the basis of a single abnormal blood glucose value or test. For an 
asymptomatic patient, at least one additional plasma/blood glucose test result with a 
value in the diabetic range is essential, either fasting blood glucose, random (casual) 
blood glucose, or from the oral glucose tolerance test.  
Non-Insulin Dependent Diabetes Mellitus (NIDDM) 
or T2DM 
 
 
 
15 
 
In epidemiological studies, one fasting plasma glucose measurement is adequate. 
Meanwhile, The WHO has reserved the use of fasting plasma glucose or 2 hours 
plasma glucose measurements for epidemiological purposes and suggested that 
ideally, both values should be used (World Health Organization, 1999). The 
diagnostic value interpretations of the fasting and 2 hours post load concentrations in 
non-pregnant subjects are listed in Table 2.1. 
 
Table 2. 1 Fasting and 2 hours post- load glucose values for diagnosis of diabetes 
mellitus and other categories of hyperglycaemia 
 
 
 
Category 
 
 
Sampling 
time 
Glucose concentration, mmol/L (mg/dl) 
 
Whole Blood 
 
Plasma 
 
Venous 
 
Capillary 
 
Venous 
 
Capillary 
 
Diabetes 
Mellitus 
 
Fasting 
 
≥ 6.1 
(110) 
 
≥ 6.1 
(110) 
 
≥ 7.0 
(126) 
 
≥ 7.0 
(126) 
 
2-hours post 
glucose load 
 
≥ 10.0 
(180) 
 
≥11.1 
(200) 
 
≥ 11.1 
(200) 
 
≥ 12.2 
(220) 
 
 
Impaired 
Glucose 
Tolerance 
(IGT) 
 
Fasting 
 
< 6.1 
(110) 
 
<6.1 
(110) 
 
< 7.0 
(126) 
 
< 7.0 
(126) 
 
 
2-hours post 
glucose load 
 
≥ 6.7 - < 10.0 
(120 – 180) 
 
≥ 7.8 - < 
11.1 
(140 – 200) 
 
≥ 7.8 - < 11.1 
(140 – 200) 
 
≥ 8.9 - < 12.2 
(160 – 220) 
 
 
 
Impaired 
Fasting 
Glycaemia 
(IFG) 
 
Fasting 
 
≥ 5.6 - < 6.1 
(100 – 110) 
 
≥ 5.6 - < 6.1 
(100 – 110) 
 
≥ 6.1 - < 7.0 
(110 – 126) 
 
≥ 6.1 - < 7.0 
(110 – 126) 
 
 
2-hours post 
glucose load 
 
< 6.7 
(120) 
 
< 7.8 
(140) 
 
< 7.8 
(140) 
 
< 8.9 
(160) 
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Adapted from the WHO Consultation Report (1999) 
 
Even though the Oral Glucose Tolerance Test is the "gold standard" for diagnosing 
diabetes, it is known to be poorly reproducible and is often not performed. In 
addition, the use of an HbA1c level to diagnose diabetes is more convenient, because 
therapeutic decisions are based on this value, regardless of the findings of the OGTT. 
An HbA1c level of 7.0% or higher often requires pharmacological intervention and is 
most often associated with the diagnosis of diabetes by World Health Organization 
standards. An HbA1c level below 7.0% should generally be treated with diet and 
exercise, regardless of the diagnosis of IGT or diabetes by OGTT. Thus, 
measurement of HbA1c levels may represent a reasonable approach to identify 
treatment-requiring diabetes (Peters et al., 1996). However, all these methods have 
their limitations in certain area because lack of accessibility and equipment to 
perform the test. 
 
The International Expert Committee (2009) with the members appointed by ADA, 
the European Association for the study of Diabetes, and the International Diabetes 
Federation had convened in 2008. This committee urged consideration for the current 
and future means of diagnosing diabetes in non-pregnant individuals by using 
HbA1c. The International Expert Committee hoped that its report would serve as a 
stimulus to both the international community and professional organizations to use 
this measure.  
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2.4 Management of T2DM 
 
Diabetes is a chronic disease that needs continuous of self-management and 
appropriate treatment. Patients need to adopt and maintain multiple self-care 
behaviours to achieve and sustain good glycaemic control (Savoca and Miller, 2001). 
The aims of diabetes management are to improve quality of life and prevent 
premature death by reducing hyperglycaemia and body fat, relief of symptoms and 
prevention of acute and chronic complications (Boulé et al., 2001). In addition, 
continuous maintenance of good glycaemic control, identification of associated risk 
factors, appropriate treatment and proper patients’ education should be conducted. 
 
Management of diabetes is very complex and needs to address the prevention of 
cardiovascular and microvascular diseases. Diabetic management includes not only 
diet and exercise, but also combinations of anti-hyperglycaemic drugs, lipid-lowering 
drug, anti-hypertensives, and anti- platelet therapies (Inzucchi et al., 2012). 
 
In recent years, new evidence has accumulated on lifestyle intervention since life-
style factors affects the incidence of T2DM (Hu et al., 2001). Self-management 
through education by self-monitoring and many other new treatments have been 
introduced. 
 
Once a diagnosis is confirmed, structured education is very important to patients and 
their family members. Structured education is an integral part of diabetes care and 
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should be organized annually with constant reinforcement (Home et al., 2008). Most 
importantly, structured education programme should be based on evidence-based 
approach. It should be tailored to individual needs, enhance self-management and has 
a formal curriculum. Structured education is usually delivered by trained educators 
using defined education resources or any trained paramedic staffs that deal with 
diabetic patients. 
 
The International Diabetes Federation Europe and the World Health Organization 
had stated an obligation to optimize the management with the aim of decreasing the 
risk of long-term complications (World Health Organization, 1999). Self-care 
behaviours is very important since persons with diabetes are expected to follow a 
complex set of behavioural actions and modification such as dietary adjustment, 
physical activity, and adherent to diabetes medications (McNabb, 1997, Meltzer et 
al., 1998). 
 
The mainstay of diabetes management is diet control since diet is known to influence 
body weight (Meyer et al., 2000). Maintaining a desirable body weight and optimal 
glycaemic control can reduce morbidity and mortality associated with diabetes 
(Savoca and Miller, 2001). Doctors or paramedics should refer patients to registered 
dieticians or diabetes educators to help them to formulate a healthy eating plan. 
Patients with T2DM need to monitor their intake of carbohydrates and reduce total 
daily calories. Controlling total fat and protein consumptions are also recommended.  
 
A study was conducted by Nelson, et al., (2002) in the Third National Health and 
Nutrition Examination Survey (NHANES III) among 1,480 adult with T2DM had 
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shown that only two thirds of the patients consumed more than 30% of their daily 
calories from fat with more than 10% of total calories from saturated fat. Thirty six 
percent of them were overweight and another 36% were obese. These results further 
complicated the diabetes management and patients might be exposed to various 
cardiovascular problems. Therefore, Medical Nutrition Therapy (MNT) is very 
important for the effective management of diabetes (Morris et al., 1997) by 
providing individualized nutritional recommendations taking into consideration the 
personal, cultural, and lifestyles preference to achieve optimum treatment (Nisak et 
al., 2013) 
 
In clinical practice, diabetic patients must strictly adhere to the diet prescriptions by 
dietitians. A well balanced diet which consists of carbohydrates, protein, fats and 
minerals is a basic requirement for every patient. On top of that, a high fibre diet 
plays an important roles to reduce cholesterol level in the blood.  The American 
Diabetes Association (ADA) recommended a moderate increase in the intake of 
dietary fibre to 20–35 g per day (Chandalia et al., 2000). They should avoid foods 
with high total calories, low dietary fibre intake, and high glycaemic load. A low 
fibre diet with a high glycaemic index has been associated with increased diabetes 
complications (Pon et al., 2006). A validated full block questionnaire consisted of 
approximately 100 food items, plus additional questions on the consumption of food 
from restaurants and the frequency of use and type of cooking fat was available and 
able to capture all nutrient in the diet (Block et al., 1990).  
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A cross sectional study was conducted by Nthangeni, et al., (2002) among 288 
T2DM to determine the dietary intake, practice, knowledge and barriers to dietary 
adherence at the urban and rural areas in South Africa. They found that urban 
subjects had higher intake of animal protein and lower ratios of polyunsaturated fat 
to saturated fat than rural subjects. Poor glycaemic control was found in both urban 
and rural areas, with more than half of the subjects having fasting plasma glucose 
above 8 mmol/L, and more than 35% having plasma glycosylated haemoglobin 
levels above 8.6%. High triglyceride levels were found in 24 to 25% of men and 17 
to 18% of women. The team also noted that obesity (body mass index ≥ 30 kg/m²) 
was higher in women with 35 to 47% and elevated blood pressure (≥ 160/95 mmHg) 
is higher (42.4%) in men at the urban area.  
 
Savoca and Miller (2001) conducted a qualitative study using semi-structured 
interview among 45 subjects with T2DM. They explore the belief and perspectives 
among patients with T2DM on dietary requirement, food selection, eating patterns 
and attitude in self-management practices. They noted that dietary self-efficacy, 
social support, and time management were identified as mediating variables that can 
influence dietary behaviours. At the same time, diabetes nutrition education 
programs increase awareness of eating behaviours and support from family members. 
 
Another study was conducted by Tan, et al., (2011) among 150 patients with T2DM 
at the Hospital USM to determine dietary compliance and its association with 
glycaemic control using a questionnaire-based interview. They found that only 
16.4% of subjects adhered to dietary regimen provided by dietitians. There was a 
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significant association between gender and fasting blood sugar with the compliance 
status.  
 
In another study by Hu, et al., (2001) among 84,941 nurses free from cardiovascular 
disease, diabetes, and cancer at the base line for 16 years, 3300 new cases from the 
subjects developed T2DM. Overweight or obesity was the single most important 
predictor of diabetes. In addition, lack of exercise, poor diet control, current 
smoking, and abstinence from alcohol use were also associated with a significantly 
increased risk of diabetes, even after adjustment for body-mass index.  
 
Exercise or physical activity improved quality of life and reduced the risk for several 
leading causes of death (Evenson and McGinn, 2005). Physical activity also reduced 
blood sugar, body fat, blood pressure, and helped to prevent cardiovascular disease. 
Therefore, it is recommended that people with type 2 diabetes get regular 30 minutes 
of moderate exercise on most days. A deliberate weight loss of 0.5 – 9.0 kilogram is 
associated with 30 – 40% reduction in diabetes related mortality (Astrup and Finer, 
2000). 
 
Regular physical activity is recommended for patients with T2DM since it may have 
beneficial effects on metabolic risk factors responsible for the development of 
diabetes complications. The non-pharmacological nature of physical activity further 
enhance the effectiveness of insulin therapy (Boulé et al., 2001). Lack of exercise 
among patients with diabetes has been associated with significant and increased risks 
of diabetes complications (Hu et al., 2001). 
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The Third National Health and Nutrition Examination Survey was performed in 
1,480 subjects with T2DM (NHANES III). The results showed that 31% reported no 
regular physical activity and another 38% reported less than recommended levels of 
physical activity. Lower income and increasing age were associated with physical 
inactivity, with 36% of the subjects were overweight and another 46% were obese 
(Nelson et al., 2002).  
 
Other than regular physical exercise, stress management is also very important. 
Stress is particularly worrisome for people with diabetes because it increases blood 
pressure and blood glucose levels. Many people with diabetes find that relaxation 
techniques can help to manage their condition. Examples include visualization, 
meditation, or breathing exercises. Taking advantage of social support networks is 
also helpful, like talking with a relative or friend, support group or counsellors. It is 
widely recognized that stress had negative effects on health in patients with diabetes 
(Surwit et al., 2002). Proper stress management was associated with small (0.5%) but 
significant reduction in HbA1c levels. 
 
Type 2 diabetes is a progressive disorder which can be initially treated with oral 
agent monotherapy, but eventually will require addition of others drugs (DeFronzo, 
1999, Qaseem et al., 2012). Oral medication is recommended for people with T2DM 
who cannot adequately control their blood sugar with diet and exercise. Many types 
of oral diabetes medications are available and usually used in combination for best 
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results. Certain drug increases insulin production, others improve the body’s use of 
insulin, while still others partially block the digestion of starches.  
 
Due to the progression of the disease, majority of patients with T2DM need multiple 
therapies such as regular diet control, regular exercise, insulin therapy, and oral 
diabetic agents such as sulphonylurea or metformin (Qaseem et al., 2012). This 
combination therapies were known to improve glycaemic control among T2DM 
(Giugliano et al., 1993; Turner et al., 1999, Qaseem et al., 2012). Whatever 
treatment that patients with T2DM received, most of them need to monitor their own 
blood sugar levels to achieve optimal glycaemic control. Self-monitoring of blood 
glucose is very important tool to help in optimizing glycaemic control, minimizing 
hypoglycaemia and maintaining quality of life (Bergenstal and Gavin III, 2005). 
Although self-monitoring of blood glucose (SMBG) is an integral part of disease 
management for patients with both type 1 and type 2 diabetes, it is still underutilized.  
 
Progression of diabetes means that patients are going through the following treatment 
stages: for the early part, diet and physical activity are aimed to achieve weight loss 
and reduce insulin needs and resistance. Then, treatment with a single drug, usually 
metformin. If not controlled, treatment with two oral drugs, usually by adding a 
sulphonylurea to the metformin. If still not controlled, treatment with three oral drugs 
in addition to insulin, usually with once-daily long-acting (basal) insulin, taken along 
with metformin and a perhaps reduced dose of sulphonylurea. Finally, when all the 
treatment above fail to achieve optimum glycaemic control, moving to more complex 
insulin regimens, such as adding short-acting insulin at mealtimes, or twice-daily 
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mixed insulins, with sulphonylurea being discontinued (Clar et al., 2010). This 
progression needs to be self-monitored regularly by diabetic patients.  
2.5 Insulin therapy among T2DM 
 
Diabetes mellitus affects people all over the world with 90% - 95% are T2DM. Type 
2 diabetes mellitus can be caused by insulin resistance, which impaired the ability of 
insulin to suppress hepatic glucose production and stimulate peripheral glucose 
uptake and secondly, progressive impairment of insulin secretion (Wallia and 
Molitch, 2014). Many patients with T2DM will eventually need insulin, as their 
ability to produce their own insulin from pancreatic beta cells decline over time 
(Hamaty, 2011). Up to 60% of patients with T2DM require insulin within 6 to 10 
years of initial diagnosis (Barag, 2011).  
 
Insulin is a potent well known drug used in treating patients with diabetes mellitus. 
Guideline by the American Diabetes Association (ADA) and the National Institute 
for Health and Clinical Excellent (NICE) stated that insulin is the most effective 
glucose-lowering agent (Davies et al., 2013).  Among the various pharmacologic 
treatments, insulin is among the most widely used drug, encompassing all cases of 
type 1 diabetes mellitus and between 20% and 30% of adult cases of T2DM 
(Anderson et al., 2004). However, delay in insulin initiation is common since about 
50% of patients with poor control T2DM did not timely start insulin therapy. The 
initiation was usually three to five years after failure of oral hypoglycaemic agents 
(Hassan et al., 2013). The first patients treated with insulin therapy in the year 1922 
was 14 years old boy Leonard Thompson with type 1 diabetes. Before the discovery 
